Loading...
BVMFFLRY3
Market cap1.13bUSD
Dec 20, Last price  
12.66BRL
1D
2.01%
1Q
-23.04%
Jan 2017
-28.19%
IPO
-16.93%
Name

Fleury SA

Chart & Performance

D1W1MN
BVMF:FLRY3 chart
P/E
16.26
P/S
1.06
EPS
0.78
Div Yield, %
7.40%
Shrs. gr., 5y
7.21%
Rev. gr., 5y
19.42%
Revenues
6.47b
+44.99%
487,588,000551,230,000675,280,000770,109,000871,541,0001,125,741,0001,501,783,0001,656,896,0001,678,900,0001,894,960,0002,096,113,0002,383,012,0002,664,463,0002,905,107,0002,971,616,0003,872,651,0004,463,040,0006,470,850,000
Net income
424m
+37.62%
32,112,00025,315,00041,962,00083,685,000130,001,000100,647,000106,588,00061,143,00085,802,000107,343,000228,749,000320,618,000331,585,000312,317,000256,961,000349,926,000307,908,000423,758,000
CFO
1.44b
+45.81%
71,329,00079,480,00072,398,00024,031,000112,919,000145,960,000167,054,000209,585,000285,709,000368,922,000513,870,000529,607,000701,485,000732,317,000647,141,0001,018,669,000987,133,0001,439,304,000
Dividend
Aug 15, 20240.33738 BRL/sh
Earnings
Mar 05, 2025

Profile

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.
URL
https://www.fleury.com.br/
IPO date
Dec 16, 2009
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,470,850
44.99%
4,463,040
15.25%
3,872,651
30.32%
Cost of revenue
5,073,471
3,388,633
2,882,361
Unusual Expense (Income)
NOPBT
1,397,379
1,074,407
990,290
NOPBT Margin
21.59%
24.07%
25.57%
Operating Taxes
110,505
96,662
144,617
Tax Rate
7.91%
9.00%
14.60%
NOPAT
1,286,874
977,745
845,673
Net income
423,758
37.62%
307,908
-12.01%
349,926
36.18%
Dividends
(510,109)
(337,201)
(296,141)
Dividend yield
5.90%
7.01%
5.71%
Proceeds from repurchase of equity
(19,380)
1,042,867
(19,780)
BB yield
0.22%
-21.67%
0.38%
Debt
Debt current
580,162
535,820
504,700
Long-term debt
5,092,363
4,260,514
3,268,174
Deferred revenue
Other long-term liabilities
1,121,395
287,609
134,701
Net debt
4,504,987
3,486,844
2,975,780
Cash flow
Cash from operating activities
1,439,304
987,133
1,018,669
CAPEX
(413,811)
(413,086)
(413,289)
Cash from investing activities
2,413
(1,384,473)
(591,363)
Cash from financing activities
(1,437,053)
380,874
(421,768)
FCF
169,425
497,684
719,306
Balance
Cash
924,133
1,309,490
797,094
Long term investments
243,405
Excess cash
843,996
1,086,338
603,461
Stockholders' equity
5,150,532
2,117,844
1,698,450
Invested Capital
9,629,518
5,580,441
4,334,378
ROIC
16.92%
19.72%
21.18%
ROCE
13.34%
15.15%
18.44%
EV
Common stock shares outstanding
484,470
338,929
336,972
Price
17.86
25.77%
14.20
-7.73%
15.39
-30.74%
Market cap
8,652,634
79.78%
4,812,789
-7.20%
5,186,002
-31.18%
EV
13,185,240
8,319,182
8,170,982
EBITDA
2,072,757
1,529,746
1,379,570
EV/EBITDA
6.36
5.44
5.92
Interest
494,568
406,851
193,721
Interest/NOPBT
35.39%
37.87%
19.56%